TGTX - TG THERAPEUTICS, INC.

29.03
-0.160   -0.551%

Share volume: 2,002,927
Last Updated: 03-05-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.31%

PREVIOUS CLOSE
CHG
CHG%
$29.19
-0.16
-0.01%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
40%
Profitability 25%
Dept financing 32%
Liquidity 50%
Performance 55%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-1.26%
1 Month
0.59%
3 Months
-5.84%
6 Months
-10.35%
1 Year
-17.50%
2 Year
59.24%
Key data
Stock price
$29.03
P/E Ratio 
12.81
DAY RANGE
$28.25 - $29.46
EPS 
$3.06
52 WEEK RANGE
$25.28 - $46.48
52 WEEK CHANGE
-$24.48
MARKET CAP 
5.732 B
YIELD 
N/A
SHARES OUTSTANDING 
158.759 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
08-05-2025
BETA 
1.40
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$2,073,710
AVERAGE 30 VOLUME 
$1,676,211
Company detail
CEO: Michael S. Weiss
Region: US
Website: tgtherapeutics.com
Employees: 290
IPO year: 2006
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

TG Therapeutics, Inc. focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The company also develops Cosibelimab, a human monoclonal antibody of IgG1 subtype that binds to programmed death-ligand 1 (PD-L1) and blocks its interactions with PD-1 and B7.1 receptors. TG-1701 is an orally available and covalently-bound Bruton's tyrosine kinase (BTK) inhibitor.

Recent news